Baxter Completes Acquisition of Synovis Baxter International Inc. announced that the company has completed its planned acquisition of Synovis Life Technologies, Inc., following approval of the transaction by Synovis shareholders. The acquisition expands Baxter’s regenerative medicine and BioSurgery franchise by adding biological and mechanical products from Synovis used for soft tissue repair and microsurgery in a variety of surgical procedures. [Baxter International Inc.] Press Release Medistem Initiates Collaboration with Chinese Conglomerate Aimed at Clinical Development of Endometrial Regenerative Cells for Critical Limb Ischemia Medistem Inc. announced initiation of joint efforts with the Chinese conglomerate, Shanghai Jia Fu Medical Apparatus Inc, in developing the Endometrial Regenerative Cell “universal donor” stem cell product for the Chinese market. The initial focus of the collaboration will be treatment of critical limb ischemia. [Medistem Inc.] Press Release Queen’s Soft Tissue Replacement Technology Gets a Funding Boost A new process for transforming discarded human fat into a soft-tissue substitute for use in reconstructive surgery is laying the groundwork for creating an Ontario-based regenerative medicine initiative focused on developing products for reconstructive and cosmetic surgery. Further development of the technology is possible through $192,500 in funding from MaRS Innovation Medical Sciences Competitive Proof of Principle. [Queen’s University] Press Release Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications Organovo Holdings, Inc. announced the successful completion of a merger with Organovo, Inc.. Concurrent with the Merger, Organovo closed a private placement consisting of approximately 6.5 million units of its securities to qualified accredited investors, for total gross proceeds of $6.5 million. [Organovo Holdings, Inc.] Press Release UniSA’s New Nanomaterials Expert Wins Fellowship Just one month into his appointment at the University of South Australia (UniSA) and Professor of Chemistry and Materials Science at the Mawson Institute, Dr Nico Voelcker, has won a prestigious Humboldt Research Fellowship to carry out a long-term research project in nanomaterials. [University of South Australia] Press Release U-M Human Embryonic Stem Cell Line Placed on National Registry The University of Michigan’s (U-M’s) first human embryonic stem cell line will be placed on the U.S. National Institutes of Health’s registry, making the cells available for federally-funded research. [University of Michigan Health System] Press Release Pathfinder Announces First European Patent Allowance for Pathfinder Cells Pathfinder Cell Therapy, Inc. announced that the European Patent Office has communicated its intent to grant Pathfinder’s first European Patent, which provides intellectual property protection for the Company’s cell-based technology throughout this region. The patent covers the Company’s proprietary Pathfinder Cells, which are a newly identified non-stem cell mammalian cell type that has demonstrated the ability to stimulate regeneration of local damaged tissue without being incorporated into the new tissue. [Reuters] Press Release UCLB Patented Technology Used to Develop a Potential New Treatment for Corneal Surface Disease Researchers at University College London (UCL) have made a significant advance towards developing a treatment for Corneal Surface Disease, using RAFTTM; a UCL Business (UCLB) patented technology licensed to Tap Biosystems. [University College London Business] Press Release bluebird bio Appoints David Davidson, M.D., as Chief Medical Officer bluebird bio announced the appointment of David M. Davidson, M.D., to the role of chief medical officer. [bluebird bio] Press Release ACT Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for Stargardt’s Disease Advanced Cell Technology, Inc. (ACT) announced that the Wills Eye Institute in Philadelphia has received institutional review board approval as a site for the company’s Phase I/II clinical trial for Stargardt’s Macular Dystrophy using human embryonic stem cell-derived retinal pigment epithelial cells. [Advanced Cell Technology, Inc.] Press Release Marina Biotech Announces Closure of Cambridge Site and Consolidation of R&D Operations in Bothell, WA Marina Biotech, Inc. announced the closure of its Cambridge site and the consolidation of all research and development efforts at its headquarters in Bothell, WA. In addition, they announced dosing of the first patient in Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with CEQ508. [Marina Biotech, Inc.] Press Release VistaGen Updates Pipeline of Stem Cell Technology-Based Drug Rescue Candidates VistaGen Therapeutics, Inc. has identified its initial Top 10 drug rescue candidates and plans to launch two formal drug rescue programs by the end of next quarter. [VistaGen Therapeutics, Inc.] Press Release |